Recent

% | $
Quotes you view appear here for quick access.

Star Scientific, Inc. (CIGX) Message Board

fjl1946 12 posts  |  Last Activity: Mar 2, 2015 8:34 AM Member since: Feb 6, 2000
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Arthritis

    by fox.samantha41 Feb 27, 2015 6:13 PM
    fjl1946 fjl1946 Mar 2, 2015 8:34 AM Flag

    Abstract

    Anatabine is a Solanaceae plant family alkaloid marketed in the United States as a dietary supplement. It has demonstrated anti-inflammatory effects in vivo and in vitro, and may be useful for musculoskeletal aches and pains. The purpose of this internet-based survey study was to provide more information about anatabine users who report benefits for joint pain or stiffness. Of the 282 survey respondents, 232 (82%) reported a benefit from anatabine supplementation for one or more joint pain conditions, most commonly the knee, wrists/hands/fingers, shoulder, and back, most often due to osteoarthritis or injury to the joint. Mean scores of joint pain and stiffness were significantly (P

    Sentiment: Strong Buy

  • Reply to

    Enduring Memory

    by repo_man_one Mar 2, 2015 5:26 AM
    fjl1946 fjl1946 Mar 2, 2015 8:22 AM Flag

    There is scarcely a human activity that is not affected by memory. To overestimate the importance of studies on memory seems impossible. Yet, all too often, we take memory for granted. Alzheimer’s disease, the most common form of dementia, is a progressive brain disease that slowly destroys a person’s memory, thinking skills and the ability to perform simple, everyday tasks. Alzheimer’s is the sixth leading cause of death in the United States and currently affects more than five million Americans, or one in nine adults over the age of 65. The number of cases is expected to triple in the next 35 years as Baby Boomers age.

    Currently, there is no cure for Alzheimer’s. Over the last 30 years, however, researchers have made remarkable progress in understanding the disease. Most recently, scientists at the Roskamp Institute in Sarasota have made discoveries that could mean a cure for the disease is on the horizon. Roskamp is a not-for-profit research facility that has been dedicated to studying Alzheimer’s and other neurological conditions. Alzheimer’s is a complex disease, involving at least three factors that disrupt the brain: neuroinflammation (the inflammation of nervous tissue), a build up of the protein beta-amyloid and problems with the protein tau.

    Scientists at Roskamp began a study a decade ago to see whether Nilvadipine, a common blood pressure medication used overseas, helped fight the beta-amyloid buildup in the brain in those patients with Alzheimer’s. They found the drug also suppressed neuroinflammation and the tau protein. Scientists started breaking down the molecule structure of the three pathologies and identified a common enzyme in all of them called syk, or spleen tyrosine kinase.

    “This new piece of data is very encouraging because it is a way to tackle these three main pathologies all together,” says Fiona Crawford, president and CEO of Roskamp Institute. “We’re optimistic that this might prove more valuable than approaches that have been used before.”

    Researchers hope to develop new drugs to inhibit syk that are suitable for clinical trials in Alzheimer’s disease. A phase three clinical trial of Nilvadipine for Alzheimer’s is currently underway in Europe. Five hundred Alzheimer’s patients in 26 clinics across nine countries are participating in the double-blind, placebo-controlled study that began in 2013. Each participant will be followed for 18 months to see if the drug is effective at slowing or stopping the course of the disease. Even if Nilvadapine does not lead to a cure, Roskamp’s recent breakthrough opens the door for other researchers to discover new therapies for Alzheimer’s.

    “We’re a little bit ahead of the game with things, but there is a lot of work to do in Alzheimer’s research,” says Crawford.“Still these new findings are very encouraging.”

    Sentiment: Strong Buy

  • 22081

    Study maps complete progress of MS for the first time in Medical News Today, David McNamee, 9 February 2015

    Excerpt:
    "In multiple sclerosis (MS), the insulating layers of nerve fibers are destroyed by chronic inflammation in the nervous system. However, the mechanisms behind the advanced stages of the disease are not fully understood, and existing treatments have a very limited effect on patients with advanced MS.

    Whether MS is caused by an as-yet unidentified infectious pathogen or an autoimmune response has not yet been established. Around 2.5 million people are affected by the condition worldwide.

    Prior to this new study, researchers had adopted two approaches to categorizing MS. One of these approaches was to think of MS as a disease of the nervous system that causes inflammation responsible for the neurodegenerative damage. The other approach was to think of MS as a disease that progresses from being an inflammatory condition into a neurodegenerative one.

    The new study - conducted by researchers from the Medical University of Vienna in Austria and published in The Lancet Neurology - suggests that the inflammatory process drives the disease from onset to the later stages, with the neurodegenerative process occurring in the progressive phase of MS

    Sentiment: Strong Buy

  • Reply to

    Anatabine Clininal Study for MS ~ UK

    by a_brown3 Feb 3, 2015 4:17 PM
    fjl1946 fjl1946 Feb 4, 2015 7:07 AM Flag

    I just typed in what A BROWN had in his message Looked like Rock Creek

    Sentiment: Strong Buy

  • Reply to

    Anatabine Clininal Study for MS ~ UK

    by a_brown3 Feb 3, 2015 4:17 PM
    fjl1946 fjl1946 Feb 3, 2015 11:05 PM Flag

    I went by what A brown said to type in and search and it came up!

  • Reply to

    Anatabine Clininal Study for MS ~ UK

    by a_brown3 Feb 3, 2015 4:17 PM
    fjl1946 fjl1946 Feb 3, 2015 5:25 PM Flag

    below is how the article was printed!!!!finally found it! thanks A _ BROWN

    Sentiment: Strong Buy

  • Reply to

    Anatabine Clininal Study for MS ~ UK

    by a_brown3 Feb 3, 2015 4:17 PM
    fjl1946 fjl1946 Feb 3, 2015 5:23 PM Flag

    Drug development company Rock Creek Pharmaceuticals, Inc. recently announced that a new clinical trial application with the United Kingdom’s Medicines Healthcare Products Regulatory Agency (MHRA) has been approved. The company is set to proceed with a Phase I study of its flagship pipeline product, Anatabine Citrate, a chemical that is found naturally in eggplant, potatoes, green tomatoes and other members of the Solanaceae family of plants, as well as in tobacco and tobacco smoke. The chemical is known for its anti-inflammatory properties unique from other anti-inflammatory drugs on the market, and may benefit patients with multiple sclerosis (MS).

    The Phase I study will be composed of three portions, designed to evaluate Anatabine’s pharmacokinetic profile in the form of modified release formulation prototypes, and its safety and tolerability profiles in healthy volunteers. The first two parts will involve an open-label, non-controlled, single-dose study on 14 healthy participants, using six formula variations, with each administered dose spaced 7-14 days apart. The variations will be distinct in dose and duration of therapeutic action. This will allow the company to determine which formulation is most ideal, based on safety. The third and last part of the Phase I study will be a double-blind, placebo-controlled, seven-day multiple dose study of the identified optimal formulation in healthy subjects.

    nicotineThe Phase I clinical trial will base its success on two outcome measures, namely: “overall safety and tolerability through physical examination, vital signs, clinical chemistry, hematology, urinalysis and observation of adverse events (AE)” and “standard pharmacokinetics (PK) parameters and also pharmacodynamic (PD) assessment, specifically measuring the impact of the drug on inflammatory processes.”

    “We are delighted to have been granted regulatory approval to begin our Phase I studies in the UK. This is the first clinical phase for our lead dr

    Sentiment: Strong Buy

  • An idea from a few followers and commenters about Anatabine

    Flora Caputo

    Chicago, IL

    Feb 1, 2015 — Hello Antabine supporters. Thank you so much for getting the word out on this petition. There has been some GOOD news about RCPI getting approvals for drug trials in the UK! But they are a long way out for getting Antabine to market as fast as we need it. For those of you desperately needing Anatabine for your health-or to even function, a few followers have suggested a plea for compassionate use to the company. I was reticent to share this until I read more about it. But the opportunity is real, and it needs to start with you reaching out to Rock Creek pleading your case. Here is what one follower suggested. At least 3 others have suggested the same.
    •••
    Write letters to RCPI describing why you need continued access to Anatabine Citrate and briefly mentioning what you were taking before that did not work for you. Those letters should be titled "UNMET MEDICAL NEEDS REQUEST"
    After the IND is accepted by the FDA, the company will forward all these letters to the FDA and seek FDA approval on "Compassionate Needs" basis.

    Rock Creek Pharmaceutical
    2040 Whitfield Avenue
    Suite 300
    Sarasota, FL 34243

    Sentiment: Strong Buy

  • fjl1946 by fjl1946 Jan 14, 2015 9:18 AM Flag

    from the hub

    I agree we need to get started and get the tissue study results out.Then the company can start saying what they really know about the compound and back it up scientifically. I believe they know what the results will be and have been holding back on disclosure...perhaps even holding back that info from potential partners which explains why they recently went back and re-confirmed that the IP was strong. I also believe they filed the CTA because they want an open public study so they have the chance to do the tissue studies ASAP and got tired of being jerked around by the FDA. The FDA is being uncooperative because they don't like that RCPI in essence did phase 1 and phase 2 studies(SUCCESSFULLY I MIGHT ADD) without FDA approval and without even filing an IND!!!

    All good news ahead...Stay the course!

    PS: Keep posting on Yahoo RockCreekPharma... you're doing a good job! !!!!

    Sentiment: Strong Buy

  • fjl1946 by fjl1946 Jan 12, 2015 7:44 AM Flag

    How To Age Well----- in Medcan Clinic, Dr. James Aw, no date

    Excerpt:
    "So what was it about the centenarians’ immune systems that allowed them to regulate their immune systems so well for so long? The answer may lie in a study published in 2011 by a researcher from the Mayo Clinic, Dr. James Kirkland. It could have something to do with the accumulation of senescent cells — so called “deadbeat” cells that stop functioning but nevertheless continue to live. The Kirkland study established that removing senescent cells in mice can extend mouse lifespans — opening the door to future treatments that extend lifespans in humans by decreasing immune-cell senescence.

    Today, clinical medicine is beginning to harness and control the chronic inflammatory process. By testing levels in the blood of a substance called hsCRP, we can now assess whether a given patient is experiencing acute inflammation — and the future is likely to bring us more sophisticated testing of chronic inflammation with such biomarkers as interleukin, insulin growth factor and tumour necrosis factor.

    Meanwhile, a new class of drugs, known as biologics, are targeting some diseases that arise from chronic inflammatory states, such as inflammatory bowel diseases, rheumatoid arthritis and autoimmune disorders.

    Could new types of biologic drugs help us control the inflammatory response associated with aging itself? Could environmental interventions, such as a customized diet, help regulate the chronic inflammatory response? And would that, in turn, help more people to live well to the age of 100? As I left Dr. Khoury’s presentation in New Orleans, I felt excited about the prospects."

    Article at:
    from the hub

    Sentiment: Buy

  • Reply to

    new sec.filing

    by fjl1946 Jan 12, 2015 7:07 AM
    fjl1946 fjl1946 Jan 12, 2015 7:13 AM Flag

    6:02 am that is early!!! presentation coming !!

    Sentiment: Buy

  • fjl1946 by fjl1946 Jan 12, 2015 7:07 AM Flag

    JAN 12 600am WAKE UP FOLKS

    Sentiment: Buy

STSI
0.58010.0000(0.00%)Jun 3 4:00 PMEDT